Sunday, September 23, 2007

Another HIV vaccine bites the dust. Bring in the cats


Merck's experimental HIV vaccine, like several others that came before it, has proven to be ineffective at preventing infection with the deadly virus. So it may be time for scientists to bite the bullet and adopt the approach used by the cat vaccine for FIV, the feline equivalent of HIV.

For the most part, scientists have resisted the approach used in the FIV vaccine for developing inoculations for use in humans because it utilizes the whole-virus. While this could stimulate a better immune response and offer greater protection from infection, there's the small chance that some of the virus may survive inactivation processes and could actually infect people.

The possibility, no matter how small, that somebody could get infected from a vaccine that's intended to protect is an ethical risk the medical community in general cannot take. But if a whole-virus vaccine could actually prevent infection and spare human life, wouldn't the greater ethical lapse be opting not to pursue this strategy, particularly in light of evidence indicating the global AIDS epidemic may be getting worse?




1 comment:

Fausto Intilla (fisico teorico) said...

Source: http://www.sciencedaily.com/releases/2007/10/071012080135.htm

Science Daily — The search for a vaccination against HIV has been in progress since 1984, with very little success. Traditional methods used for identifying potential cellular targets can be very costly and time-consuming.
The key to creating a vaccination lies in knowing which parts of the pathogen to target with which antibodies. A new study by David Heckerman and colleagues from Massachusetts General Hospital, publishing in PLoS Computational Biology, has come up with a way to match pathogens to their antibodies.
At the core of the human immune response is the train-to-kill mechanism in which specialized immune cells are sensitized to recognize small peptides from foreign pathogens (e.g., HIV). Following this sensitization, these cells are then activated to kill cells that display this same peptide. However, for sensitization and killing to occur, the pathogen peptide must be "paired up" with one of the infected person's other specialized immune molecules--an HLA (human leukocyte antigen) molecule. The way in which pathogen peptides interact with these HLA molecules defines if and how an immune response will be generated.
Heckerman's model uses ELISpot assays to identify HLA-restricted epitopes, and which HLA alleles are responsible for which reactions towards which pathogens. The data generated about the immune response to pathogens fills in missing information from previous studies, and can be used to solve a variety of similar problems.
The model was applied to data from donors with HIV, and made 12 correct predictions out of 16. This study, says David Heckerman, has "significant implications for the understanding of...vaccine development." The statistical approach is unusual in the study of HLA molecules, and could lead the way to developing an HIV vaccine.
Citation: Listgarten J, Frahm N, Kadie C, Brander C, Heckerman D (2007) A statistical framework for modeling HLA-dependent T cell response data. PLoS Comput Biol 3(10): e188. doi:10.1371/journal.pcbi.0030188
Note: This story has been adapted from material provided by Public Library of Science.

Fausto Intilla
www.oloscience.com

Sports News

News of the Odd